NICE is unable to recommend the use in the NHS of canakinumab (Ilaris) for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from Novartis.

Is this guidance up to date?

We reviewed the evidence in February 2020. We will withdraw this appraisal when the guideline on the management of gout is published, which will make recommendations on canakinumab.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)